Novartis receives FDA approval for Rhapsido, first treatment for symptomatic dermographism

Novartis received FDA approval for Rhapsido (remibrutinib), the first treatment for adults with symptomatic dermographism who do not achieve adequate control with H1 antihistamines. The approval was disclosed by the company.

Detected & updated continuously · Source: Nebula